WZ4002

製品コードS1173

WZ4002化学構造

分子量(MW):494.18

WZ4002は一種の新たで、突然変異的で、選択性的なEGFR阻害剤で、EGFR(L858R)/(T790M)に作用することで、BaF3細胞系の中でIC50値が2 nM/8 nMです。WZ4002はERBB2リン酸化(T798I)に抑制作用を表しません。

サイズ 価格(税別) 在庫  
JPY 18094.00 あり
JPY 19920.00 あり
JPY 61420.00 あり
JPY 111220.00 あり

カスタマーフィードバック(5)

  • Antitum o r activity of WZ4002 and/or E7050 in mouse xenograft models of human tumors. SCID mice-bearing PC-9/Vec (A), PC-9/HGF#5 (B), H1975 (C), or HCC827ER (D) tumors were administered 25 mg/kg WZ4002 and/or E7050 once daily for 14 to 21 days. Tumor volume was measured using calipers on the indicated days. Mean?SE tumor volumes are shown for groups of 4 to 5 mice.

    Mol Cancer Ther 2012 11, 2149-57. WZ4002 purchased from Selleck.

    (A) Cells were treated with or without the indicated doses of WZ4002 for 5 h. EGFR-related signal molecules were assessed using Western blot analysis.

    Oncotarget, 2016, 7(16):22005-15. WZ4002 purchased from Selleck.

  • (a) Western blots examine the effects of WZ4002 alone or a combination of WZ4002 and ABT-263 in H1975 parental or SR cells in suspension. Cells were grown for 48 h and then treated with the indicated pharmacological agent(s) for another 24 h. The cleaved/total poly (ADP-ribose) polymerase-1 (PARP-1) ratio determined for each cell line using Image J software is also represented. The values are the means of three independent experiments. (b) Quantification of apoptotic cells assessed by PARP-1 cleavage from each cell line.

    Lab Invest 2011 92, 371-383. WZ4002 purchased from Selleck.

    Caspase 3/7 activation in H1975 SR cells and HCC827 cells. Cells were seeded and left in suspension for 24 h, and then untreated or treated with the indicated drug(s) for another 24 h before being assessed. Caspase activity was evaluated by using the Caspase-Glo 3/7 assay and normalized to a 1.0 arbitrary unit for the mean of three untreated wells.

    Lab Invest 2011 92, 371-383. WZ4002 purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of WZ4002 by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan.

    Dr. Yong-Weon Yi from Georgetown University Medical Center. WZ4002 purchased from Selleck.

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

製品説明 WZ4002は一種の新たで、突然変異的で、選択性的なEGFR阻害剤で、EGFR(L858R)/(T790M)に作用することで、BaF3細胞系の中でIC50値が2 nM/8 nMです。WZ4002はERBB2リン酸化(T798I)に抑制作用を表しません。
ターゲット
EGFR (L858R) [1]
(BaF3 cells)
EGFR (L858R/T790M) [1]
(BaF3 cells)
2 nM 8 nM
体外試験

WZ4002 inhibits other EGFR genotypes E746_A750 and E746_A750/T790M with IC50 of 2 and 6 nM. Besides, WZ4002 suppresses widetype ERBB2 with an IC50 of 32 nM. WZ4002 inhibits EGFR, AKT and ERK1/2 phosphorylation in NSCLC cell lines and WZ4002 prevents of EGFR phosphorylation in NIH-3T3 cells expressing different EGFR T790M mutant alleles. For WZ4002, kinases that exhibited greater than 95% inhibition relative to the DMSO control at 10 μM are selected for measurement of their dissociation constants. WZ4002, which possesses an ortho-methoxy group at the C2-aniline substituent, is more selective for EGFR compared to WZ3146. WZ4002 is 100-fold less effective at inhibiting phosphorylation of WT EGFR compared to the quinazoline inhibitors. Similarly, WZ4002 prevents EGFR kinase activity of recombinant L858R/T790M protein more potently than of WT EGFR, while the opposite is observed with HKI-272 and gefitinib. [1] In addition, the phosphorylated EGFR of Src TKI-resistant H1975 cells, as well as HCC827 cells, is completely suppressed by the third generation EGFR TKI, WZ4002. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 cells NVT2fnVZTnWwY4Tpc44h[XO|YYm= Mo[wOlAhdWmwcx?= NU\5dXBQUW6qaXLpeIlwdiCxZjDFS2ZTKEx6NUjSJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBU\jliY3XscJMheHKnLXnuZ5Vj[XSnZDDmc5IhPjBibXnud{Bj\W[xcnWgd5Vje3S{YYTlJIFv\CCDVGCgZYRlcXSrb36gZpkhcG:vb3flcoVwfXNidHnt[U1z\XOxbI\l[EBHWkWWIHHzd4F6NCCLQ{WwQVEhdk1? NVXjWFR3OjZ{N{WwNlg>
mouse BA/F3 cells NGqx[4dRem:uaX\ldoF1cW:wIHHzd4F6 M2LtV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOgeJJidnOoZXP0[YQhf2m2aDDFS2ZTKEV5NE\fRVc2OF:mZXyvWFc6OE1ibYX0ZY51NCCHQ{WwQVIhdk1? Ml;aNlEzODh6MEK=
human HCC827 cells Mlr4VJJwdGmoZYLheIlwdiCjc4PhfS=> NYLNPYhFPzJiaB?= MlT2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiZHXsJGU4PDZvQUe1NEBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD15IH7N M2HWb|IzOzN7M{Sy
human PC9 cells NXLzPXZQWHKxbHnm[ZJifGmxbjDhd5NigQ>? M1Tv[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[5Jwf3SqLYLld4l{fGGwdDDoeY1idiCSQ{mgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEV5NE\fRVc2OC:WN{mwUUBufXSjboSsJGVEPTB;MUSgcm0> NIrOWnMzOTJyOEiwNi=>
NCI-H1975 cells M2\FTGZ2dmO2aX;uJIF{e2G7 MWKyJIg> MnHRTY5pcWKrdHnvckBw\iCHR1\SJGw5PTiUL2S5O|BOKGSxdXLs[UBufXSjboSgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF7DTU1JOTl5NTDj[YxteyCjZoTldkAzKGi{czDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUC9NE4xOjNizszN MX6yN|k{ODl7NB?=
human 16HBE cells NGW5cG9Rem:uaX\ldoF1cW:wIHHzd4F6 NEnGNoE4OiCq NHj1W|ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEG2TGJGKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWJRmKgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkixNUDPxE1? MX:yN|c6OjNzOB?=
human A431 cells NILWfY1EgXSxdH;4bYNqfHliYYPzZZk> M3HaclczKGh? MnHER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BwfmW{ZYjwdoV{e2mwZzD3bYxlKHS7cHWgSWdHWiCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTFwMUC4JO69VQ>? MVyyN|Y3QDR2MR?=
human LoVo cells MmjSSpVv[3Srb36gZZN{[Xl? NInuPZYzKGh? MU\Jcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDMc3ZwKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OD1zLkG4JO69VQ>? NUXENXJKOjN7M{C5PVQ>
human 16HBE14o- cells  M3vyeGN6fG:2b4jpZ4l1gSCjc4PhfS=> MlTDO|IhcA>? MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxOmhDTTF2bz2gZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDFS2ZTKGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OS5|NUWg{txO MWeyN|Y3QDR2MR?=
human BEAS2B cells MYHDfZRwfG:6aXPpeJkh[XO|YYm= MYK3NkBp NEG1eJpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDTUGVMlKgZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDFS2ZTKGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OS56MUGg{txO MVOyN|Y3QDR2MR?=
human A549 cells M1zi[nBzd2yrZnXyZZRqd25iYYPzZZk> M3\m[lczKGh? NYDaeYE1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBsNVKDUzDk[ZBmdmSnboSgbJVu[W5iQUW0PUBk\WyuczDveoVz\XiycnXzd4lv\yCZVDDFS2ZTKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9Nk4yODJizszN MYiyOFYxPzV7MR?=
human HL7702 cells M1noNnBzd2yrZnXyZZRqd25iYYPzZZk> M{nUe|czKGh? NGrZWGxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMO|cxOiClZXzsd{BmgHC{ZYPzbY5oKHerbISgeJlx\SCHR1\SJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;Mj63N{DPxE1? NH\nNZEzOjN|OUO0Ni=>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In a 2-week efficacy study, WZ4002 treatment results in significant tumor regressions compared to vehicle alone in both T790M containing murine models. [1] Treatment with low-dose WZ4002, and high-dose WZ4002 leads to mean decreases in tracer uptake of 26%, and 36%, respectively. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

EGFR kinase assays:

In vitro inhibitory enzyme kinetic assays using recombinant EGFR L858R/T790M and WT protein and are performed using the ATP/NADH coupled assay system in a 96-well format. WZ4002 is added to determine its inhibitory effects.
細胞試験: [1]
+ 展開
  • 細胞株: NSCLC, Ba/F3 cells, NIH-3T3 cells, PC9GR4 cells
  • 濃度: 0-1 μM
  • 反応時間: 72 hours
  • 実験の流れ: The NSCLC, Ba/F3 cells, NIH-3T3 cells, PC9GR4 cells are used and verified to contain EGFR delE746_A750/T790M by direct sequencing. Cell proliferation and growth assays are performed using the MTS assay. Site directed mutagenesis is performed using the Quick Change Site-Directed Mutagenesis kit.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: EGFR-TL (T790M/L858R) mice
  • 製剤: NMP (10% 1-methyl-2-pyrrolidinone: 90% PEG-300
  • 投薬量: 25mg/kg
  • 投与方法: Gavage
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 13 mg/mL (26.3 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 494.18
化学式

C25H27ClN6O3

CAS No. 1213269-23-8
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

EGFR信号経路図

EGFR Inhibitors with Unique Features

相関EGFR製品

Tags: WZ4002を買う | WZ4002 ic50 | WZ4002供給者 | WZ4002を購入する | WZ4002費用 | WZ4002生産者 | オーダーWZ4002 | WZ4002化学構造 | WZ4002分子量 | WZ4002代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID